Geron Corp (NASDAQ: GERN) reported Q4 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20).

“2019 was a pivotal year for Geron as we completed the imetelstat program transition, assembled an impressive in-house team with a proven track record in drug development, and advanced imetelstat into late-stage development with the opening of our IMerge Phase 3 clinical trial in lower risk myelodysplastic syndromes,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer. “In 2020, we plan to complete enrollment in IMerge, announce our decision regarding any potential late-stage development plans for myelofibrosis by mid-year, and commence a proof of concept study in additional hematologic myeloid malignancies. With a strong team in place to execute these plans, we look forward to further advancing the development of imetelstat.”

For earnings history and earnings-related data on Geron Corp (GERN) click here.